Nanotherapeutics: New challenges for safety and cost-effectiveness regulation in Australia

Medical Journal of Australia

Volumn 186, Issue 4, 2007, Pages 189-191

  Faunce, Thomas A ^a  

^a The Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; ANTIBIOTIC AGENT; CANCER VACCINE; DENDRIMER; DNA VACCINE; HEPARIN; IMMUNOMODULATING AGENT; IRON OXIDE; NANOPARTICLE; NANOTUBE; SILICON; TITANIUM DIOXIDE; VIVAGEL; ZINC OXIDE;

ANALYTICAL EQUIPMENT; ARTICLE; AUSTRALIA; BIOENGINEERING; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; MEDICAL INSTRUMENTATION; MEDICAL TECHNOLOGY; NANOTECHNOLOGY; NONVIRAL GENE THERAPY; RISK ASSESSMENT; SAFETY; URINE CATHETER; VIRUS LIKE AGENT;

EID: 33847692752     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2007.tb00860.x     Document Type: Article

References (35)

1. US Food and Drug Administration. Regulation of nanotechnology products. http://www.fda.gov/nanotechnology/regulation.html (accessed Aug 2006).
2. Sone J, Fujita J, Ochiai Y, et al. Nanofabrication toward sub-10nm and its application to novel nanodevices. Nanotechnology 1999; 10: 135-141.
3. Brower V. Is nanotechnology ready for primetime? J Natl Cancer Inst 2006; 98: 9-11.
4. Hofmann H. Supraparamagnetic nanoparticles, a multifunctional tool for medical imaging, drug and gene delivery and cancer treatment [abstract]. Australian Research Council Nanotechnology Network International Conference on Nanoscience and Nanotechnology; 2006 Jul 3-7; Brisbane, Australia.
5. Gras SL, Squires AM, Dobson CM. Functionalised amyloid fibrils for bionanotechnology [abstract]. Australian Research Council Nanotechnology Network International Conference on Nanoscience and Nanotechnology; 2006 Jul 3-7; Brisbane, Australia.
6. Lipin DI, Chuan YP, Neibert M, et al. Processing and in vitro assembly of virus-like-particles [abstract]. Australian Research Council Nanotechnology Network International Conference on Nanoscience and Nanotechnology; 2006 Jul 3-7; Brisbane, Australia.
7. Kendall M. Micro-nanoprojections on patches for targeted delivery of genes and drugs to the skin [abstract]. Australian Research Council Nanotechnology Network International Conference on Nanoscience and Nanotechnology; 2006 Jul 3-7; Brisbane, Australia.
8. Fernandez-Lopez S, Kim HS, Choi EC, et al. Antibacterial agents based on the cyclic D,L-alpha-peptide architecture. Nature 2001; 412: 452-455.
9. Bottini M, Bruckner S, Nika K, et al. Multi-walled carbon nanotubules induce T lymphocyte apoptosis. Toxicol Lett 2006; 160: 121-126.
10. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001; 294: 1537-1540.
11. Mumper RJ, Cui Z. Genetic immunization by jet injection of targeted pDNA-coated nanoparticles. Methods 2003; 31: 255-262.
12. Roy I, Ohulchanskyy TY, Bharali DJ, et al. Optical tracking of organically modified silica nanoparticles as DNA carriers: a nonviral, nanomedicine approach for gene delivery. Proc Natl Acad Sci U S A 2005; 102: 279-284.
13. Brenner B. New nanotechnology receives FDA approval setting stage for new era in battle against hospital related infections [press release]. AcryMed, 12 Dec 2005. http://www.acrymed.com/PR121205.htm (accessed Aug 2006).
14. Prestidge CA. Nanoscience facilitating the development of novel pharmaceutical delivery systems [abstract]. Australian Research Council Nanotechnology Network International Conference on Nanoscience and Nanotechnology; 2006 Jul 3-7; Brisbane, Australia.
15. Gertner M. Nanotechnology and its impact on clinical medicine. Nanotechnol Law Business 2004; 1: 147-155.
16. Aitken RJ, Creely KS, Tran CL. Nanoparticles: an occupational hygiene review. Edinburgh: Institute of Occupational Medicine for the Health and Safety Executive, 2004. http://www.hse.gov.uk/research/rrhtm/rr274.htm (accessed Nov 2006).
17. Australian Department of Employment and Workplace Relations. Submission to inquiry into workplace exposure to toxic dusts and nanoparticles. Canberra: DEWR, 2005. http://www.aph.gov.au/SENATE/COMMITTEE/clac_ctte/ toxic_dust/submissions/sub11.pdf (accessed Nov 2006).
18. Therapeutic Goods Administration. The TGA's risk management approach. http://www.tga.gov.au/about/tgariskmnt.htm (accessed Aug 2006).
19. Flinders Consulting Pty Ltd. A review of the potential occupational health and safety implications of nanotechnology. Canberra: Australian Safety and Compensation Council, 2006, http://www.ascc.gov.au/ascc/ AboutUs/Publications/ResearchReports/ AReviewofthePotentialOccupationalHealthandSafetyImplicationsof Nanotechnology.htm (accessed Aug 2006).
20. Pammolli F, Riccaboni M, Oglialoro C, et al. Medical devices: competitiveness and impact on public health expenditure. Rome: European Commission, 2005. http://www.cermlab.it/_documents/MD_Report.pdf (accessed Nov 2006).
21. Chaudhry Q, Blackburn J, Floyd P, et al. A scoping study to identify gaps in environmental regulation for the products and applications of nanotechnologies. London: UK Department of Environment, Food and Rural Affairs, 2006.
22. Nordan MM, Holman MW. A prudent approach to nanotechnology environmental, health and safety risks. Ind Biotechnol 2005; 1: 146-149.
23. Baluch AS. Angstrom Medica: securing FDA approval and commercializing a nanomedical device. Nanotechnol Law Business 2005; 2: 168-173.
24. Till MC, Simkin MM, Maebius S. Nanotech meets the FDA: a success story about the first nanoparticulate drugs approved by the FDA. Nanotechnol Law Business 2005; 2: 163-167.
25. Ray WA, Stein CM. Reform of drug regulation - beyond an independent drug-safety board. N Engl J Med 2006; 354: 194-201.
26. Therapeutic Goods Administration. A review of the scientific literature on the safety of nanoparticulate titanium dioxide and zinc oxide sunscreens. http://www.tga.gov.au/npmeds/sunscreen-zotd.pdf (accessed Nov 2006).
27. Global Harmonization Task Force. Working towards harmonization in medical device regulation. http://www.ghtf.org (accessed Mar 2006).
28. Fisher E, Jones J, von Schomberg R, editors. Implementing the precautionary principle: perspectives and prospects. Cheltenham, UK: Edward Elgar, 2006.
29. Faunce TA, Johnston K, Bambrick H. The Trans-Tasman Therapeutic Products Authority: potential AUSFTA impacts on safety and cost-effectiveness regulation for medicines and medical devices in New Zealand. Victoria University of Wellington Law Review 2006; 37: 365-390.
30. Mnyusiwalla A, Daar AS, Singer PA. "Mind the gap": science and ethics in nanotechnology. Nanotechnology 2003; 14: R9-R13.
31. Taylor RS, Drummond MF, Salkeld G, Sullivan SD. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 2004; 329: 972-974.
32. Faunce T, Doran E, Henry D, et al. Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy. Global Health 2005; 1: 1-15.
33. Medical Services Advisory Committee. Performance report 2003-05. Canberra: MSAC, 2005. http://www.msac.gov.au/internet/msac/ publishing.nsf/Content/annual-report-1 (accessed Nov 2006).
34. The Senate, Commonwealth of Australia. Senate Inquiry into Workplace Exposure to Toxic Dusts and Nanoparticles. Final report. Canberra, The Senate, 2006. http://www.aph.gov.au/SENATE/committee/clac_ctte/ toxic_dust/report/report.pdf (accessed Nov 2006).
35. Homer JB, Hirsch GB. System dynamics modeling for public health: background and opportunities. Am J Public Health 2006; 96: 452-458.